{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin-Related+%28ATTR%29+Familial+Amyloid+Polyneuropathy&page=2",
    "query": {
      "condition": "Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin-Related+%28ATTR%29+Familial+Amyloid+Polyneuropathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T04:10:33.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03759379",
      "title": "HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis, Hereditary",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        },
        {
          "name": "Vutrisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 164,
      "start_date": "2019-02-14",
      "completion_date": "2025-11-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 15,
      "location_summary": "La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03759379"
    },
    {
      "nct_id": "NCT03431896",
      "title": "Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloidosis",
        "Amyloid",
        "Amyloid Neuropathies, Familial",
        "Amyloid Cardiomyopathy",
        "Amyloid - Primary",
        "Transthyretin Amyloidosis",
        "AL Amyloidosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 37,
      "start_date": "2018-02-01",
      "completion_date": "2026-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03431896"
    },
    {
      "nct_id": "NCT05023889",
      "title": "Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Polyneuropathies",
        "Wild Type ATTR Amyloidosis",
        "Wild-Type Transthyretin-Related (ATTR)Amyloidosis",
        "Wild-Type Transthyretin Cardiac Amyloidosis",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "patisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Austin Neuromuscular Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-08-03",
      "completion_date": "2026-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05023889"
    },
    {
      "nct_id": "NCT03860935",
      "title": "Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis",
        "Amyloid Cardiomyopathy",
        "Transthyretin Amyloidosis",
        "Cardiomyopathies",
        "Heart Diseases"
      ],
      "interventions": [
        {
          "name": "acoramidis",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 632,
      "start_date": "2019-03-19",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 40,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03860935"
    },
    {
      "nct_id": "NCT05374564",
      "title": "Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiomyopathies, Primary"
      ],
      "interventions": [
        {
          "name": "(18F)Flutemetamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-16",
      "completion_date": "2024-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374564"
    },
    {
      "nct_id": "NCT06563895",
      "title": "Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis",
        "Amyloid Cardiomyopathy",
        "Transthyretin Amyloidosis",
        "Cardiomyopathies",
        "Heart Diseases",
        "Polyneuropathies"
      ],
      "interventions": [
        {
          "name": "Acoramidis",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 587,
      "start_date": "2025-05-12",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 39,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 30 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06563895"
    },
    {
      "nct_id": "NCT05758493",
      "title": "Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis",
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "124I-Evuzamitide",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 150,
      "start_date": "2023-01-10",
      "completion_date": "2028-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05758493"
    },
    {
      "nct_id": "NCT04513600",
      "title": "ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Cardiac MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "The Christ Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 131,
      "start_date": "2020-08-01",
      "completion_date": "2023-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04513600"
    },
    {
      "nct_id": "NCT04899180",
      "title": "Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Aortic Stenosis",
        "Transthyretin Amyloidosis",
        "Transthyretin Amyloid Cardiomyopathy",
        "Transthyretin Cardiac Amyloidosis"
      ],
      "interventions": [
        {
          "name": "99mTc-PYP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "75 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "75 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-07-14",
      "completion_date": "2024-01-05",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04899180"
    },
    {
      "nct_id": "NCT05577819",
      "title": "Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Transthyretin Amyloidosis",
        "Heart Failure",
        "Heart Failure, Diastolic",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "99mTc-pyrophosphate Scintigraphy",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 515,
      "start_date": "2020-10-02",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-06-10T04:10:33.129Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05577819"
    }
  ]
}